Who we are
Diversity and Inclusion
Penta Foundation Italy
Penta ID Innovation
News & Events
Penta Aperitivo Webinars
Work with us
Call for services
Brighter Future Award
PENTA 15: plasma pharmacokinetic study of once versus twice daily abacavir and lamivudine as part of combination antiretroviral therapy in HIV-1 infected children aged 3 to <36 months.
PENTA 15: Once-daily abacavir and lamivudine as part of combination antiretroviral therapy to 48 weeks in HIV-1 infected children aged 3 to 36 months.
Adherence to ART and acceptability of planned treatment interruptions (PTI) in the PENTA 11 trial
Effect of early antiretroviral therapy on the risk of AIDS/death in HIV infected infants: the European Infant Collaborative Study.
Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants.